Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization

European Journal of Medicinal Chemistry

Volumn 52, Issue , 2012, Pages 205-212

  Xie, Hui ^a   Zeng, Lili ^a   Zeng, Shaogao ^a   Lu, Xin ^a   Zhang, Guicheng ^a   Zhao, Xin ^a   Cheng, Na ^a   Tu, Zhengchao ^a   Li, Zhiyuan ^a   Xu, Hongjiang ^b   Yang, Ling ^b   Zhang, Xiquan ^b   Huang, Min ^c   Zhao, Junling ^a   Hu, Wenhui ^a,d  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d State Key Laboratory of Respiratory Disease   (China)

Author keywords

DPP IV inhibitor; Oral glucose tolerance test; PK driven optimization; Pyrrolopyrimidine analogues; Type 2 diabetes

Indexed keywords

2 [[2 (3 AMINOPIPERIDIN 1 YL) 4 OXO 4,7 DIHYDRO 3H PYRROLO[2,3 D]PYRIMIDIN 3 YL]METHYL]BENZONITRILE; 2 [[2 (3 AMINOPIPERIDIN 1 YL) 6 BROMO 4 OXO 4H PYRROLO[2,3 D]PYRIMIDIN 3(7H) YL]METHYL]BENZONITRILE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; PYRROLOPYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT;

ABSORPTION; ANIMALS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DESIGN; DRUG STABILITY; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; MICE; PYRIMIDINES; PYRROLES;

EID: 84860342035     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.03.015     Document Type: Article

References (36)

1. P.A. Hollander, and P. Kushner Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors Postgrad. Med. 122 2010 71 80
2. T. Abel, and J. Feher A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin) Orv Hetil 151 2010 1012 1016
3. C.F. Deacon, J.J. Holst, and R.D. Carr Glucagon-like peptide-1: a basis for new approaches to the management of diabetes Drugs Today (Barc) 35 1999 159 170
4. B. Gallwitz Diabetes therapy-novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors) MMW Fortschr Med. 152 2010 43 44
5. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber (2R)-4-oxo-4-[3-(trifluoromethyl) -5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 141 151
6. D. Kim, J.E. Kowalchick, L.L. Brockunier, E.R. Parmee, G.J. Eiermann, M.H. Fisher, H. He, B. Leiting, K. Lyons, G. Scapin, S.B. Patel, A. Petrov, K.D. Pryor, R.S. Roy, J.K. Wu, X. Zhang, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines J. Med. Chem. 51 2008 589 602
7. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.E. Dunning, B.L. Mangold, M.D. Mone, M.E. Russell, S.C. Weldon, and T.E. Hughes 1-[2-[(5-Cyanopyridin-2- yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbon itrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 45 2002 2362 2365
8. E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, and A.J. Garber Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin Diabetes Care 30 2007 890 895
9. V. Fonseca, A. Schweizer, D. Albrecht, M.A. Baron, I. Chang, and S. Dejager Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Diabetologia 50 2007 1148 1155
10. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 5025 5037
11. J. Feng, Z. Zhang, M.B. Wallace, J.A. Stafford, S.W. Kaldor, D.B. Kassel, M. Navre, L. Shi, R.J. Skene, T. Asakawa, K. Takeuchi, R. Xu, D.R. Webb, and S.L. Gwaltney 2nd Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 50 2007 2297 2300
12. M. Eckhardt, E. Langkop, M. Mark, M. Tadayyon, L. Thomas, H. Nar, W. Pfrengle, B. Guth, R. Lotz, P. Sieger, H. Fuchs, and F. Himmelsbach 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J. Med. Chem. 50 2007 6450 6453
13. J. Deng, L. Peng, G. Zhang, X. Lan, C. Li, F. Chen, Y. Zhou, Z. Lin, L. Chen, R. Dai, H. Xu, L. Yang, X. Zhang, and W. Hu The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes Eur. J. Med. Chem. 46 2011 71 76
14. D.G. Bourke, C.J. Burns, A.N. Cuzzupe, J.T. Feutrill, M.R. Kling, T.L. Nero, N-Containing Heterocyclic Compounds, WO(2009)/062258.
15. Y.H. Song, Q. Xu, A. Pandey, Protein kinase inhibition, WO(2009)/026107.
16. Z. Zhang, M.B. Wallace, J. Feng, J.A. Stafford, R.J. Skene, L. Shi, B. Lee, K. Aertgeerts, A. Jennings, R. Xu, D.B. Kassel, S.W. Kaldor, M. Navre, D.R. Webb, and S.L. Gwaltney Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV J. Med. Chem. 54 2011 510 524
17. B. Ruttens, P. Blom, S. Van Hoof, I. Hubrecht, J. Van der Eycken, B. Sas, J. Van Hemel, and J. Vandenkerckhove Carbohydrate-based macrolides prepared via a convergent ring closing metathesis approach: in search for novel antibiotics J. Org. Chem. 72 2007 5514 5522
18. D.M. Shendage, R. Frohlich, and G. Haufe Highly efficient stereoconservative amidation and deamidation of alpha-amino acids Org. Lett. 6 2004 3675 3678
19. H. Liu, S.B. Ko, H. Josien, and D.P. Curran Selective N-Functionalization of 6-Substituted-2-Pyridones Tetrahedron Lett. 36 1995 8917 8920
20. A. Orita, D. Hasegawa, T. Nakano, and J. Otera Double elimination protocol for synthesis of 5,6,11,12-tetradehydrodibenzo[a, e]cyclooctene Chemistry 8 2002 2000 2004
21. F. Alonso, I.P. Beletskaya, and M. Yus Non-conventional methodologies for transition-metal catalysed carbon-carbon coupling: a critical overview. Part 2: the Suzuki reaction Tetrahedron 64 2008 3047 3101
22. M. Takano, R. Yumoto, and T. Murakami Expression and function of efflux drug transporters in the intestine Pharmacol. Ther. 109 2006 137 161
23. T. Murakami, and M. Takano Intestinal efflux transporters and drug absorption Expert Opin. Drug Metab. Toxicol. 4 2008 923 939
24. R.H. Ho, and R.B. Kim Transporters and drug therapy: implications for drug disposition and disease Clin. Pharmacol. Ther. 78 2005 260 277
25. L.M. Chan, S. Lowes, and B.H. Hirst The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability Eur. J. Pharm. Sci. 21 2004 25 51
26. S. Ekins, and P.W. Swaan Development of computational models for enzymes, transporters, channels, and receptors relevant to ADME/Tox Rev. Comp. Ch. 20 2004 333 415
27. T.R. Stouch, and O. Gudmundsson Progress in understanding the structure-activity relationships of P-glycoprotein Adv. Drug Deliv. Rev. 54 2002 315 328
28. M.V. Varma, O.P. Perumal, and R. Panchagnula Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery Curr. Opin. Chem. Biol. 10 2006 367 373
29. I.K. Pajeva, C. Globisch, and M. Wiese Structure-function relationships of multidrug resistance P-glycoprotein J. Med. Chem. 47 2004 2523 2533
30. S. Winiwarter, N.M. Bonham, F. Ax, A. Hallberg, H. Lennernas, and A. Karlen Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach J. Med. Chem. 41 1998 4939 4949
31. K. Palm, P. Stenberg, K. Luthman, and P. Artursson Polar molecular surface properties predict the intestinal absorption of drugs in humans Pharm. Res. 14 1997 568 571
32. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
33. H. vandeWaterbeemd, G. Camenisch, G. Folkers, and O.A. Raevsky Estimation of Caco-2 cell permeability using calculated molecular descriptors Quant. Struct.-Act. Rel. 15 1996 480 490
34. E. Raschi, V. Vasina, E. Poluzzi, and F. De Ponti The hERG K+ channel: target and antitarget strategies in drug development Pharmacol. Res. 57 2008 181 195
35. R. Pearlstein, R. Vaz, and D. Rampe Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior J. Med. Chem. 46 2003 2017 2022
36. B. Lee, L. Shi, D.B. Kassel, T. Asakawa, K. Takeuchi, and R.J. Christopher Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys Eur. J. Pharmacol. 589 2008 306 314